ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes.

The drug was shown to reduce the incidence of the composite renal outcome by 44% compared with placebo treatment, with highly significant statistical significance (HR 0.56; 95% CI: 0.45–0.68), regardless of the degree of filtrate reduction or the extent of pre-existing albuminuria.

also in 132,142 other papers